title: Screen of FDA-approved drug library reveals compounds that protect hair cells from aminoglycosides and cisplatin.
abstract: Loss of mechanosensory hair cells in the inner ear accounts for many hearing loss and balance disorders. Several beneficial pharmaceutical drugs cause hair cell death as a side effect. These include aminoglycoside antibiotics, such as neomycin, kanamycin and gentamicin, and several cancer chemotherapy drugs, such as cisplatin. Discovering new compounds that protect mammalian hair cells from toxic insults is experimentally difficult because of the inaccessibility of the inner ear. We used the zebrafish lateral line sensory system as an in vivo screening platform to survey a library of FDA-approved pharmaceuticals for compounds that protect hair cells from neomycin, gentamicin, kanamycin and cisplatin. Ten compounds were identified that provide protection from at least two of the four toxins. The resulting compounds fall into several drug classes, including serotonin and dopamine-modulating drugs, adrenergic receptor ligands, and estrogen receptor modulators. The protective compounds show different effects against the different toxins, supporting the idea that each toxin causes hair cell death by distinct, but partially overlapping, mechanisms. Furthermore, some compounds from the same drug classes had different protective properties, suggesting that they might not prevent hair cell death by their known target mechanisms. Some protective compounds blocked gentamicin uptake into hair cells, suggesting that they may block mechanotransduction or other routes of entry. The protective compounds identified in our screen will provide a starting point for studies in mammals as well as further research discovering the cellular signaling pathways that trigger hair cell death.
authors.affiliation: Virginia Merrill Bloedel Hearing Research Center, University of Washington, Box 357923, Seattle, WA 98195-7923, USA. avlasits@berkeley.edu
authors.forename: Anna L
authors.initials: AL
authors.lastname: Vlasits
authors.forename: Julian A
authors.initials: JA
authors.lastname: Simon
authors.forename: David W
authors.initials: DW
authors.lastname: Raible
authors.forename: Edwin W
authors.initials: EW
authors.lastname: Rubel
authors.forename: Kelly N
authors.initials: KN
authors.lastname: Owens
mesh_terms: D000617:Aminoglycosides / Q000037:antagonists & inhibitors* / Q000633:toxicity; D000818:Animals; D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors / Q000633:toxicity; D000970:Antineoplastic Agents / Q000037:antagonists & inhibitors / Q000633:toxicity; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D005839:Gentamicins / Q000037:antagonists & inhibitors / Q000633:toxicity; D006198:Hair Cells, Auditory / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007612:Kanamycin / Q000037:antagonists & inhibitors / Q000633:toxicity; D053403:Lateral Line System / Q000187:drug effects / Q000473:pathology; D040542:Mechanotransduction, Cellular / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009355:Neomycin / Q000037:antagonists & inhibitors / Q000633:toxicity; D018696:Neuroprotective Agents / Q000494:pharmacology*; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology; D015027:Zebrafish
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D005839:Gentamicins; D018696:Neuroprotective Agents; D020845:Selective Estrogen Receptor Modulators; D007612:Kanamycin; D009355:Neomycin; D002945:Cisplatin